Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736553 · ClinicalTrials.gov registry record
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development
A clinical trial, sponsored by Ohio State University.
- Completed
- Registry status
- 53
- Enrollment target
NCT01736553 is a clinical trial that has completed, run by Ohio State University. The registered enrollment target is 53 participants.
The verdict
NCT01736553 has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
Spinal muscular atrophy (SMA) is the leading genetic cause of death of infants. Strong preclinical evidence suggests that effective therapy must be delivered as early as possible to prevent progression of the disease. The primary study objective will be to identify prognostic and surrogate biomarkers of disease progression that will facilitate the execution of therapeutic SMA clinical trials in infants.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736553
The ClinicalTrials.gov registry entry for NCT01736553 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01736553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01736553 about?
NCT01736553 is a clinical study titled "Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development". Spinal muscular atrophy (SMA) is the leading genetic cause of death of infants. Strong preclinical evidence suggests that effective therapy must be delivered as early as possible to prevent progression of the disease. The primary study objective will be to identify prognostic and surrogate biomarker...
What is the current status of trial NCT01736553?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2012-12. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT01736553?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.